An HBV lookalike that is actually a hollow envelope containing three
proteins derived from mammal cells. When it is injected, the body
produces protective antibodies against all three of these proteins,
offering unprecedented effectiveness.
Since 1982, developing countries have been vaccinating newborns
against the hepatitis B virus (HBV). Yet this leading cause of
life-threatening liver infection remains a major global health problem
directly affecting some two billion people and many more as silent
Why? Solving this riddle is what enabled the scientists at Israel’s
SciGen to pioneer the world’s only commercially available
third-generation vaccine against the virus that causes 1.2 million
deaths every year.
SciGen CEO Michal Ben-Attar explains that Sci-B-Vac is the most
effective and cost-efficient solution to combating HBV anywhere, and is
especially needed in Africa where the rates of infection are high.
Almost every newborn in Israel already receives this cutting-edge
inoculation on the day of birth, and the formula is registered for use
also in Hong Kong, the Philippines, India, Vietnam, Georgia and Central
Africa, with approvals in the United States and other countries expected
in the near future.
Labels: Sci-B-Vac vaccine